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Heparin-induced thrombocytopenia after
implantation of a heparin-bonded
polytetrafluoroethylene lower extremity bypass
graft: A case report and plan for management
Subhash Thakur, MD,a John P. Pigott, MD,a and Anthony J. Comerota, MD, RVT,a,b Toledo, Ohio; and
Ann Arbor, Mich
The proprietary heparin-bonded expanded polytetrafluoroethylene graft appears to be an attractive option for lower
extremity revascularization in patients with compromised runoff and no autogenous vein. There is no detectable elution
of heparin from the graft surface, but antithrombotic activity has been detected in devices implanted for >2 years.
Although 15,000 Propaten (W. L. Gore and Associates, Flagstaff, Ariz) grafts have been implanted, to our knowledge,
this is the first report of heparin-induced thrombocytopenia developing from this heparin-bonded graft. The heparin-
induced thrombocytopenia responded promptly to graft explantation. Amanagement plan is suggested for patients being
considered for this graft. ( J Vasc Surg 2009;49:1037-40.)Heparin, a highly efficient anticoagulant and platelet
inhibitor, has recently been bonded to polytetrafluoroeth-
ylene (PTFE) grafts used for lower extremity bypass to
improve patency. A heparin-bonded graft would seem to be
a good option for lower extremity revascularization in
patients with critical limb ischemia and no autogenous vein,
especially in those with compromised runoff. A concern
with the use of heparin-bonded prostheses is the develop-
ment of heparin-induced thrombocytopenia (HIT) in a
patient who undergoes insertion of such a prosthetic.
Propaten (W. L. Gore and Associates, Flagstaff, Ariz) is
an expanded PTFE (ePTFE) graft with unfractionated
heparin (UFH) bound to its surface using a proprietary end
point attachment mechanism (Carmeda BioActive Surface
[CBAS], Carmeda AB, Upplands Väsby; Sweden).1 Results
of infrainguinal bypass with this heparin-bonded graft show
improved patency compared with standard prostheses.2-4 It
therefore appears to be an appropriate conduit choice for
lower extremity bypass in a patient with compromised
runoff from a popliteal aneurysm facing a 5-year patency
rate of 50% for standard prostheses.5
This article reports for the first time, to our knowledge,
a case of HIT that developed in a patient in association with
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guinal revascularization. We also present a management
algorithm for patients being considered for heparin-
bonded ePTFE grafts.
CASE REPORT
A 79-year-old man presented with the recent onset of left leg
and foot edema. His medical history included hypertension, hyper-
lipidemia, and chronic renal insufficiency. His medical history
included open repair of an abdominal aortic aneurysm, four-vessel
coronary artery bypass grafting using both great saphenous veins,
repair of an iatrogenic ascending aortic dissection, and a left carotid
endarterectomy.
On physical examination he had normally palpable femoral
pulses. Both popliteal pulses were prominent, with the left sugges-
tive of a popliteal artery aneurysm. Pedal pulses were absent. He
had swelling of the left leg and foot. A noninvasive evaluation with
arterial duplex confirmed bilateral popliteal aneurysms, 3 cm on
the right side and 6 cm on the left. His ankle-brachial index (ABI)
was 0.61 on the left and 1.03 on the right.
The patient underwent arteriography to clarify the aneurysmal
disease and options for lower extremity revascularization. Because
of the larger symptomatic popliteal artery aneurysm on the left
side, it was operated on first. A Propaten graft (8-mm diameter,
approximately 25-cm long) was used as the bypass conduit from
the middle superficial femoral artery to the tibioperoneal trunk
using a vein patch at the distal anastomosis. The popliteal artery
was ligated proximally and distal to the aneurysm. The patient was
anticoagulated with 6000 IU UFH intraoperatively. Completion
arteriography revealed good filling of contrast in the peroneal
artery and no technical problem at the anastomosis.
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Aventis, Bridgewater, NJ) at a dose 70 mg every 12 hours as
adjunctive anticoagulation, and therapy with a preoperative aspirin
dose of 81 mg/d was continued. His postoperative course was
complicated by nausea and confusion, and he was not tolerating his
diet.
Routine blood analysis on postoperative day 9 revealed
severe thrombocytopenia, with a platelet count of 11 103/L
(Fig 1). Lovenox was stopped, and he was started on an argatro-
ban drip according to a standard weight-based protocol for a
suspected diagnosis of HIT, which was confirmed by elevated
heparin antibodies at 3.58 (reference range: 0.349, negative;
0.35-0.45, borderline; 0.45, positive). His platelet count
remained low, reaching a nadir of 8  103/L after 4 days of
argatroban therapy.
The heparin bound to the ePTFE graft was thought to be
responsible for the persistent thrombocytopenia; therefore, ex-
plantation of the heparin-bonded graft was recommended with
replacement of a standard 7-mm PTFE graft. The procedure was
performed while the patient was anticoagulated with argatroban.
Once explanted, the graft was returned to the manufacturer, where
it was found to contain friable, nonocclusive clots; however, the
graft itself was unremarkable.
After graft explant, the patient’s platelet count began to rise
24 hours and reached a nearly normal (preoperative) baseline
value by 7 days after explant (Fig 1). The patient was then con-
verted to oral anticoagulation with Coumadin (Bristol-Myers
Squibb, New York, NY) and continued taking aspirin (81 mg/d).
His platelet count plateaued at approximately 100  103/L and
remained at that level long-term.
At the 5-month follow-up visit, the patient’s platelet count
was 154  103/L, and the Coumadin was stopped for a nonva-
scular surgical procedure. At 6 months, his ABIs were 1.14 (right
leg) and 1.11 (left), and a duplex examination demonstrated a
Fig 1. The drop in the patient’s platelet count is shown in relation
to graft insertion, treatment of heparin-induced thrombocytope-
nia, and graft explant.patent graft with good flow.DISCUSSION
Heparin-induced thrombocytopenia is a potentially dev-
astating complication associated with the use of UFH and,
to a lesser extent, low-molecular-weight heparin (LMWH)
preparations.6 HIT is classically defined as a drop in pa-
tients’ platelet count by 50% while receiving UFH or
LMWH. It typically occurs 5 to 14 days after heparin
exposure, assuming that the patient has had no previous
exposure.7 Patients with recent prior exposure may have
existing heparin antibodies that can cause a rapid, precipi-
tous thrombocytopenia, which can cause acute thrombosis.
Thrombotic complications occur in up to 50% of HIT
patients and are most commonly venous.8 Potential com-
plications include deep venous thrombosis (DVT) of the
arms and legs, pulmonary embolism (PE), cerebral vein
thrombosis, adrenal vein thrombosis, or venous limb gan-
grene. Acute limb ischemia, stroke, myocardial infarction,
cardiac thrombus or embolus, andmesenteric, renal, spinal,
or arterial thrombosis also have been reported.6-8 Heparin-
induced thrombocytopenia can cause acute graft thrombo-
sis after lower extremity bypass as a result of platelet depo-
sition at the sites of vascular injury.
HIT is a clinical pathologic syndrome diagnosed by link-
ing heparin to thrombocytopenia and identifying heparin-
dependant antibodies. It is caused by heparin-dependent im-
munoglobulin G (IgG) antibodies that activate platelets
through their Fc receptors.9,10 Heparin binds to platelet
factor 4 (PF4) released from the  granules within the
activated platelets. PF4 heparin is the target antigen and
leads to the formation of IgG (HIT) antibodies in certain
patients. The PF4 heparin and IgG antibody form an
immune complex stimulating additional activation by at-
taching to platelet Fc receptors,11 resulting in Fc stimula-
tion. This leads to the generation of procoagulant-rich
platelet microparticles thought to be responsible for the
venous and arterial thrombosis associated with HIT.
Based on clinical presentation, HIT is divided into two
types. Type I HIT is associated with a mild thrombocyto-
penia and usually occurs 4 days of starting heparin. It is
non-immune-mediated and appears to be caused by direct
agglutinating effect of heparin on platelets. Type I is not
associated with thrombosis and resolves spontaneously de-
spite continuation of treatment. Type II HIT is associated
with severe thrombocytopenia or a significant fall in base-
line platelet count, or both, usually occurring between 5
and 14 days after heparin is started. Type II is immune-
mediated and may be associated with both arterial and
venous thrombosis.
Results of early use of the heparin-bonded PTFE grafts
are encouraging. Bosiers et al3 reported 1-year primary
patency rates of 84% and 74% for femoropopliteal and
femorocrural bypasses, with corresponding 96% and 100%
secondary patency rates. In the 86 patients treated, HIT
was not identified.
Walluscheck et al4 reported a 2-year primary patency
rate of 81% for below knee bypasses with limb salvage of
98% using the same prosthesis. Therefore, these encourag-
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bypass of the tibioperoneal trunk with single-vessel runoff.
The Propaten graft has heparin molecules covalently
bound to its surface by the proprietary CBAS end point
attachment mechanism,1 which anchors the heparin mole-
cule to the graft surface while maintaining the intrinsic
bioactive property of heparin. This design is intended to
leave a persistently thrombus-resistant surface but not allow
heparin to escape into the circulation. Heyligers et al12
tested whether there were detectable amounts of heparin
released into the circulation by studying markers of in vivo
platelet activation and blood coagulation in 10 patients in
whom the Propaten vascular graft was used. They found no
differences in markers of in vivo activation of platelets or
blood coagulation between patients who received a Propaten
graft and the control ePTFE grafts. Although antibodies
against heparin were not found in any of the 10 patients
studied, this cohort of patients was too small to make any
statement about HIT induction.
Unfractionated porcine heparin is bound in an esti-
mated dose of 400 IU/15 cm of an 8-mm Propaten
endoprosthesis. Although a small dose, investigators have
reported sustained bioactivity up to 12 weeks in a canine
model.2 Bioactivity was preserved at 855 days on the sur-
face of a ventricular assist device in which the CBAS tech-
nology was used to bind heparin to its surface.13
This is a very small dose of heparin compared with the
amount of UFH the patient received intraoperatively and
the amount of LMWH received postoperatively. In vitro
experiments have shown that 20 IU of heparin are re-
leased into solution during the hours after flow is estab-
lished through the graft; thereafter, heparin release could
not be detected (personal communication fromW. L. Gore
and Associates, Aug 4, 2008).
This patient received LMWH in addition to UFH
during the perioperative period. Although LMWH is
known to cause HIT, the likelihood of it causing HIT is
low. HIT studies have been performed in randomized trials
and prospective studies comparing LMWH vs UFH, with
much less HIT with LMWH, showing an odds ratio of 0.1
(95%CI, 0.03-0.33, P.001).14 The absolute risk forHIT
with LMWH is about 0.2%, which is less than one-tenth
that of UFH.14 Because this patient’s platelet count re-
mained low after LMWHwas stopped and did not increase
until the graft was removed, we believe UFH and perhaps
LMWH (known cross-reactivity) was the cause of the HIT.
The graft may or may not have contributed to antibody
production; however, it appears that the graft was respon-
sible for the persistent thrombocytopenia.
The pathophysiology of HIT may vary between UFH
and LMWH. Experimentally, it has been shown that the
size of the heparin molecule may determine its affinity for
PF4.15 This may reduce the likelihood of HIT with
LMWH compared with the larger UFH molecules. This
observation may have relevance when explaining the low
number of HIT cases identified by the manufacturer as a
result of the Propaten graft. Although more than 15,000
Propaten grafts have been inserted worldwide, the manu-facturer has been notified of only 10 instances of HIT
developing in these patients (personal communication,
W. L. Gore and Associates, July 18, 2008). This is substan-
tially lower than one would anticipate from data in patients
routinely exposed to UFH. This may be due to the reduced
exposure of the heparin molecule by the end point covalent
bonding process. A large part of the heparin molecule may
be consumed or altered as a result of binding, leaving the
active pentasaccharide portion of the heparin molecule
exposed to flowing blood.
The pentasaccharide part of the molecule is unlikely to
cause HIT. Fondaparinux is a pure pentasaccharide, and to
date, only one patient has been reported to have hadHIT as
a complication of treatment.8 We believe that the exposed
pentasaccharide portion of the heparin molecules bound to
the graft are unlikely to be associated with HIT. The
remaining portion of the heparin molecule exposed to
Fig 2. Suggested protocol for patients considered as candidates
for heparin-bonded prosthesis. ASA, aspirin; HIT, heparin-
induced thrombocytopenia; UFH, unfractionated heparin.flowing blood is more likely to be responsible. The end-
JOURNAL OF VASCULAR SURGERY
April 20091040 Thakur et allinked covalent bonding is capable of interacting with
PF4.16 It is possible that covalent heparin-bonded devices
could result in formation of HIT antibodies, cause HIT in
a patient that has formed antibodies, or be responsible for
persistent thrombocytopenia when HIT develops from
other exogenous administration.
Because many patients with critical limb ischemia who
require lower extremity revascularization will have been
exposed to UFH or LMWH, it is possible that heparin
antibody production has been initiated and antibodies can
be present before the insertion of a heparin-bound endo-
prosthesis. HIT is a morbid and potentially fatal condition;
therefore, patients who have been exposed to heparin 6
months should be tested for heparin antibodies before the
insertion of a heparin-bonded prosthesis. If the result is
positive, a heparin-bonded prosthesis should be avoided.
Heparin antibodies are unlikely to be present in patients
who have not received heparin within 6 months; of
course, a negative antibody test result does not preclude the
patient from developing HIT in the future.
Although the likelihood of HIT developing as a result
of the Propaten graft appears to be low, we recommend the
close monitoring of the patient’s platelet count postopera-
tively to recognize HIT if indeed it develops. If it occurs, all
heparin should be discontinued and treatment with a direct
thrombin inhibitor started. Our choice is argatroban, un-
less the patient has compromised liver function, in which
case lepirudin is used. Danaparoid can also be used where it
is available.7 Heparin antibody studies and serotonin re-
lease assays should be performed in all patients who develop
thrombocytopenia. If HIT is confirmed, the entire heparin-
bonded graft should be explanted and an alternative pros-
thesis inserted (assuming the patient has no autogenous
vein). Argatroban or another direct thrombin inhibitor is
used intraoperatively and postoperatively. Delay in effective
management of HIT is associated with an escalated risk of
thrombotic events, both venous and arterial.
It is our policy to treat these patients with long-term
warfarin and aspirin; however, warfarin should not be ini-
tiated until the platelet count returns to nearly normal
levels to avoid warfarin-induced skin necrosis. Ourmanage-
ment algorithm for a patient considered a candidate for a
heparin-bonded prosthesis is summarized in Fig 2.
CONCLUSIONS
The heparin-bonded Propaten ePTFE graft appears to
have improved patency rates compared with standard pros-
theses. Patients at risk of having established heparin anti-
bodies should be tested before the graft is inserted. Should
HIT develop in a patient after the graft is inserted, all
heparin should be discontinued, the patient prescribed a
nonheparin anticoagulant, and the graft explanted, with an
alternative, non-heparin-bound prosthesis inserted. Theproprietary CBAS heparin-bonding process may be respon-
sible for the lower than anticipated rate of HIT reported
with the use of the Propaten graft.
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